|
AI-Driven Prognostic and Predictive Model for Muscle-Invasive Bladder Cancer
Application
This AI-driven prognostic and predictive model aims to predict outcomes for muscle-invasive bladder cancer (MIBC) patients undergoing neoadjuvant chemo-immunotherapy, aiding in treatment decision-making and patient stratification.
Key Benefits
Harnesses nuclear morphology and architectural features for precise prognostication in MIBC...
Published: 3/2/2026
Contributor(s): Kamal Hammouda, Tilak Pathak, Anant Madabhushi, Tuomas Mirtti
|
|
Predictive Model for Post Surgery Prostate Cancer Recurrence
Application
An artificial intelligence based prognostic model for early Biochemical recurrence (BCR) risk assessment of men post-radical prostatectomy.
Key Benefits
Identifies significant features, including tumor-infiltrating lymphocytes (TIL), in prostate cancer recurrence.
Market Summary
Prostate cancer is one of the most diagnosed cancers...
Published: 3/2/2026
Contributor(s): Sebastian Medina, Kamal Hammouda, Tilak Pathak, Anant Madabhushi, Tuomas Mirtti
|
|
Precision Neo-Cysteine Molecular Glues to Restore Protein-Protein Interactions in Disease
Application
Molecular glues designed to selectively bind mutated neo-cysteine residues and restore disease-disrupted protein–protein interactions (PPIs), offering a precision therapeutic approach for conditions such as cancer where loss or weakening of critical protein interactions drives tumor growth and progression.
Key Benefits
Provides...
Published: 3/2/2026
Contributor(s): Xiulei Mo, Haian Fu
|
|
Next Gen Immune-Optimized Gene Delivery
Application
An advanced gene therapy approach that improves therapeutic efficiency by protecting transgene expressing cells from host immune responses, through modulation of a key immune checkpoint pathway.
Key Benefits
Enhanced efficiency across viral and non-viral gene delivery systems, including AAV, lentivirus, LNPs, and electroporation.
Enables...
Published: 2/23/2026
Contributor(s): Matthew (Matt) Gardner, Michael Kuipa, Abubakarr Koroma, Isai Leguizamo
|
|
Non-invasive Diagnostic for Meningiomas
Application
A non-invasive molecular diagnostic tool that reliably predicts the tumor characteristics and risk of recurrence of meningiomas.
Key Benefits
Combines meningioma gene expression data, construction of a gene interaction network, and tumor histology data to diagnose and predict clinical outcomes.
Complete analytical handling from specimen...
Published: 1/28/2026
Contributor(s): Ali Alawieh, Youssef Ismail, Tomas Garzon-Muvdi
|
|
HomeTown: A Mobile App Guiding Care for Patients with Cancer Predisposition Syndromes
Application
A mobile application to inform patients with cancer predisposition syndrome on the type and frequency of cancer screening and surveillance that they need.
Key Benefits
Focused on several cancer predisposition syndromes with an option to expand.
Provides screening recommendations as per national guidelines, to hopefully allow for risk-reduction...
Published: 1/26/2026
Contributor(s): Bojana Pencheva, Morgan Greenleaf, Maren Parsell, Christopher Porter, Sarah Mitchell, Santiago Arconada Alvarez, Robert (Rob) Mannino, Wilbur Lam
|
|
Methioninase Inducing Virus for Anti-Cancer Therapy
Application
A set of viral constructs that induce regulatable expression of methionine degrading enzyme for treatment of brain tumors.
Key Benefits
Built-in Tet-responsive element ensures precise regulation, preventing unwanted enzyme activity.
IL-2 signal directs the enzyme for secretion, optimizing its therapeutic impact.
Specific delivery...
Published: 1/20/2026
Contributor(s): Timothy R. Gershon, Leon McSwain, Andrey Tikunov
|
|
Small Molecule Inhibitors Targeting OTUD4-CD73 Interaction for Immune-Cold Tumors
Application
This technology introduces small molecule inhibitors, ST80 and Z22, to disrupt the protein-protein interaction (PPI) between OTUD4 and CD73. These inhibitors enhance tumor immunogenicity by reducing CD73 stabilization, improving the immune response in triple-negative breast cancer (TNBC) and other immune-cold tumors.
Key Benefits
ST80...
Published: 1/20/2026
Contributor(s): Yong Wan, Yueming Zhu, Ivet Bahar, Anupam Banerjee, Jiyoung Lee
|
|
Gene Editing for Head and Neck Cancer Treatment
Application
Method for delivering gene-editing therapeutic in head and neck cancers.
Key Benefits
CRISPR/CAS9-based gene editing mechanism targeting novel disease-modifying gene.
Liquid nanoparticle encapsulation permitting in vivo delivery.
Market Summary
Head and neck cancers (HNC) are the 7th most common global cancer, accounting for 3%...
Published: 11/7/2025
Contributor(s): Yong Teng, Yamin Li
|
|
Anticancer Agent with N-Glycan Specificity
Application
An engineered protein for targeting disease-associated N-glycans.
Key Benefits
High affinity, pH insensitive, no cofactors required.
Applications in anticancer and antiviral therapeutics and research.
Can aid in manufacturing monoclonal antibodies with desired N-glycosylation properties.
Market Summary
Glycosylation involves post-translation...
Published: 1/20/2026
Contributor(s): Eric J. Sundberg, Diego Sastre, Maros Huliciak
|
